🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

782 results for “S.A.” Clear

  1. PolyCore

    Pharma Mar S.A.

    Congestive Heart Failure

    phase 3 small molecule active

    1 trial
  2. Powder for reconstitution for enteral administration

    Pharma Mar S.A.

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial
  3. Powder for reconstitution for enteral administration

    Pharma Mar S.A.

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial
  4. Pozelimab, Cemdisiran

    Pharma Mar S.A.

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial
  5. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule and tablet, Normal Saline, Prednisolon STADA® 10 mg Tabletten, [1-13C]SODIUM ACETATE, Avalotcagene ontaparvovec

    Pharma Mar S.A.

    Late-onset Ornithine transcarbamylase (OTC) deficiency

    phase 3 small molecule active

    1 trial
  6. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule, 10 mg, Prednisolone Placebo hard capsule, 5mg, Prednisolon STADA® 10 mg Tabletten, Pariglasgene brecaparvovec, Normal Saline

    Pharma Mar S.A.

    Glycogen Storage Disease Type Ia (GSDIa)

    phase 3 small molecule active

    1 trial
  7. Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln

    GlaxoSmithKline Biologicals S.A.

    Varicella

    phase 3 small molecule active

    1 trial
  8. ProAir® Digihaler®, Placebo TEV-56248, Albuterol Sulfate HFA, ArmonAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate

    Pharma Mar S.A.

    Asthma

    phase 3 small molecule active

    1 trial
  9. Prolastin 1000 mg, Pulver und Lösungsmittel zur Her- stellung einer Infusionslösung, Prolastin 5000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Prolastin 4000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Instituto Grifols S.A.

    Severe Alpha-1 Antitrypsin Deficiency (AATD)

    phase 3 small molecule active

    1 trial
  10. QL2107, PEMBROLIZUMAB

    Pharma Mar S.A.

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial
  11. Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch

    Pharma Mar S.A.

    Post-surgical neuropathic pain

    phase 3 small molecule active

    1 trial
  12. RANOLAZINE, FLECARDIA Διάλυμα για ένεση/έχχυση

    Pharma Mar S.A.

    Restoration of sinus rhythm in patients with recent AF onset

    phase 3 small molecule active

    1 trial
  13. REGN4461 - Mibavademab

    Pharma Mar S.A.

    Monogenic obesity

    phase 3 small molecule active

    1 trial
  14. REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508

    Pharma Mar S.A.

    Thromboembolic disease

    phase 3 small molecule active

    1 trial
  15. RITUXIMAB, Capsule, hard, Calquence 100 mg hard capsules, BENDAMUSTINE

    Pharma Mar S.A.

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial
  16. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Pharma Mar S.A.

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial
  17. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Pharma Mar S.A.

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial
  18. Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Pharma Mar S.A.

    Paroxysmal nocturnal haemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial
  19. Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection

    Pharma Mar S.A.

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial
  20. Sovateltide, Sovateltide matching placebo

    Pharma Mar S.A.

    Acute cerebral ischemic stroke

    phase 3 small molecule active

    1 trial
  21. Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation

    GlaxoSmithKline Biologicals S.A.

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial
  22. Sterile normal saline (0.9% sodium chloride solution), ADX-324

    Pharma Mar S.A.

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial
  23. Sunitinib AqVida 12,5 mg Hartkapseln, QINLOCK 50 mg tablets

    Pharma Mar S.A.

    Patients with Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial
  24. T89 Placebo; capsules contain brown coated dripping pills., Nitroglycerin Orifarm 0,5 mg tabletes lietošanai zem mēles

    Pharma Mar S.A.

    Stable Angina Pectoris

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources